About this trial
Individuals with repaired Tetralogy of Fallot (rTOF) remain at risk for sudden cardiac death from ventricular tachycardia (VT). Transcatheter pulmonary valve replacement (TPVR) indications continue to broaden, yet its capability to reduce the risk of VT and sudden cardiac death remains unknown. Thus, in a cohort of participants with rTOF who are presenting for TPVR the investigators intend to: (1) quantify and localize right ventricular (RV) isthmuses with abnormal voltage and/or conduction velocity; (2) identify which RV isthmuses are at risk of being "jailed" by TPV prostheses; and (3) explore the feasibility of omnipolar technology to characterize wavefront directionality and differentiate slow conduction from conduction block.
Eligibility criteria
Qualifiers
Diagnosis of tetralogy of Fallot (TOF) or double outlet right ventricle (DORV)
Referred for transcatheter pulmonary valve replacement (TPVR) per routine clinical indications
Weight >=25 kg
Disqualifiers
None
Trial design
Treatments tested in this trial
- Electroanatomic substrate mapping
Treatment groups
Sponsors and collaborators
Boston Children's Hospital
Lead sponsor
Abbott
Collaborator